CALGARY, AB — May 6, 2026 — Leads & Copy —
Seegnal (TSXV:SEGN) announced today that it remains unable to file its audited annual consolidated financial statements for the year ended December 31, 2025, along with related documents, by the prescribed deadline.
The delay, according to the company, is due to the time required by its recently engaged external auditor to complete final internal procedures before issuing an audit opinion. Seegnal stated it is working with its auditor to complete the filings and expects to file them on or before May 13, 2026.
Seegnal previously applied to the Alberta Securities Commission, the British Columbia Securities Commission, and the Ontario Securities Commission for a management cease trade order (MCTO). The MCTO, if issued, would prohibit the company’s CEO and CFO from trading Seegnal’s securities while the order is in effect.
If an MCTO is issued, the general investing public will still be able to trade the company’s common shares listed on the TSX Venture Exchange (TSXV). However, during the MCTO period, the CEO and CFO will be restricted from trading the company’s shares, and the company will be unable to issue or acquire securities from insiders or employees, except under legally binding obligations.
Seegnal confirms its intent to comply with alternative information guidelines outlined in National Policy 12-203, including issuing bi-weekly default status reports, while it remains in default of the filing requirement. The company also confirms it is not subject to any insolvency proceedings.
The company stated that there is no other undisclosed material information relating to its affairs, other than what was disclosed in the release.
The MCTO, if issued, will remain in effect until the company files the annual filings or the MCTO is revoked or varied.
Seegnal aims to address adverse drug effects through its clinical decision support system, integrating patient-specific data to reduce alert overload for clinicians and improve medication safety. Seegnal’s SaaS technology integrates data such as genetics, lab results, ECG, smoking habits, allergies, food preferences, gender, age, and the effects of concomitant medications. The company says institutions using its platform have reported reductions in admissions and medication consumption, as well as time savings in prescription renewals.
Seegnal is marketing its SaaS-based platform in Israel, the UAE, the United Kingdom, the United States, and Poland. In Israel, Seegnal’s patient-specific standard has been adopted by the Ministry of Health as the new standard in governmental hospitals. The platform is currently used daily by over 10,000 clinicians in Israel.
Source: Seegnal
